P/E at 34.86 vs Industry's 37.18: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: A Slight Discount in a Premium Sector

The current P/E of 34.86 for Sun Pharmaceutical Industries Ltd is approximately 6.2% below the industry average of 37.18. While the sector is characterised by elevated valuations reflecting growth expectations and innovation pipelines, this discount suggests a more cautious market stance on the stock relative to peers. This valuation gap may reflect concerns over recent operational challenges or competitive pressures, but it also indicates that the stock is not trading at an excessive premium. Sun Pharma’s market capitalisation of ₹4,40,398 crores places it firmly in the large-cap category, underscoring its significance within the Pharmaceuticals & Biotechnology sector.

Performance Across Timeframes: Divergent Momentum Signals

Examining the stock’s returns reveals a complex momentum profile. Over the past year, Sun Pharmaceutical Industries Ltd has delivered a 12.54% gain, outperforming the Sensex which declined by 9.58% during the same period. This outperformance extends to longer horizons as well, with three-year and five-year returns of 62.64% and 143.78% respectively, significantly ahead of the Sensex’s 12.81% and 26.62% gains. However, the short-term picture is less robust: the stock’s one-month return is down 1.95%, though this still compares favourably to the Sensex’s 3.65% decline. The three-month return of 1.45% also outpaces the Sensex’s negative 2.72%, indicating some resilience despite recent volatility. This divergence between short-term softness and longer-term strength raises questions about the sustainability of momentum — is this a temporary pause or the start of a more significant shift?

Moving Average Configuration: Signs of Recovery Amidst a Larger Trend

The technical setup for Sun Pharmaceutical Industries Ltd is characterised by a mixed moving average configuration. The stock price currently sits above its 200-day moving average, a positive long-term signal suggesting underlying strength. However, it remains below the 5-day, 20-day, 50-day, and 100-day moving averages, indicating short- and medium-term pressure. This pattern often reflects a recent bounce within a broader downtrend or consolidation phase. The 1.54% gain on the latest trading day, in line with the sector’s 1.54% move, may signal the beginning of a recovery attempt — is this a genuine recovery or a relief rally that will fade at the 50 DMA? — the moving average configuration provides the clearest answer.

Relative Performance Versus the Sensex

Over multiple timeframes, Sun Pharmaceutical Industries Ltd has consistently outperformed the Sensex. The year-to-date return of 8.38% contrasts sharply with the Sensex’s 12.33% decline, while the one-week and one-day performances also show positive alpha. This relative strength is notable given the broader market weakness and suggests that the stock has been a defensive performer within the Pharmaceuticals & Biotechnology sector. However, the 10-year return of 139.50% trails the Sensex’s 162.09%, indicating that over the very long term, the stock has lagged the broader market. This mixed relative performance invites the question — should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Sector Context: Mixed Results Amidst Industry Volatility

The Pharmaceuticals & Biotechnology sector has seen a varied set of results recently, with 28 stocks having declared results so far. Of these, 13 reported positive outcomes, 11 were flat, and 4 posted negative results. This distribution reflects a sector grappling with both growth opportunities and headwinds such as regulatory scrutiny and pricing pressures. Within this environment, Sun Pharmaceutical Industries Ltd’s performance and valuation appear to be in line with sector dynamics, neither markedly outperforming nor lagging peers in valuation terms.

Rating Reassessment: Previously Rated Buy

MarketsMOJO had previously assigned a Buy rating to Sun Pharmaceutical Industries Ltd, reflecting confidence in its fundamentals and growth prospects. The rating was updated on 03 Sep 2026, signalling a reassessment of the company’s outlook. While the current rating is not disclosed, the data-driven approach highlights the importance of valuation, momentum, and technical factors in the new assessment. What is the current rating for Sun Pharmaceutical Industries Ltd following this reassessment?

Conclusion: A Balanced Valuation and Mixed Momentum Profile

The data for Sun Pharmaceutical Industries Ltd paints a picture of a large-cap pharmaceutical stock trading at a modest discount to its sector’s P/E, with a solid track record of outperformance over one, three, and five years. The recent short-term momentum is less clear-cut, with the stock below most short- and medium-term moving averages despite holding above the 200-day average. This suggests a phase of consolidation or tentative recovery rather than a decisive trend shift. The sector’s mixed results and the company’s rating reassessment add further complexity to the investment case — should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today